gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Cytochrome P450, family 19, subfamily A, polypeptide 1

aromatase
Top mentioned proteins: CAN, HAD, AGE, V1a, iMpact
Papers using aromatase antibodies
Morphological and functional changes induced by the amino acid analogue 3-nitrotyrosine in mouse neuroblastoma and rat glioma cell lines
Supplier
Farina V. et al., In European Journal of Histochemistry : EJH, 2003
... were blocked for 20min with normal goat serum and incubated overnight at 4°C with a polyclonal anti-aromatase antibody obtained from rabbit (5 µg/mL, Acris, Hiddenhausen, Germany) diluted 1:200, ...
Neoadjuvant therapy of endometrial cancer with the aromatase inhibitor letrozole: endocrine and clinical effects
Supplier
Sun Qing-Yuan et al., In Reproductive Biology and Endocrinology : RB&E, 2001
... Anti-aromatase antibody was purchased from Novus Biologicals (Novus Biologicals, Littleton, CO) ...
Papers on aromatase
Ethnic differences in initiation and timing of adjuvant endocrine therapy among older women with hormone receptor-positive breast cancer enrolled in Medicare Part D.
New
Du et al., Houston, United States. In Med Oncol, Feb 2016
Logistic regression models were performed to assess the association between race/ethnicity and the initiation of tamoxifen, aromatase inhibitors (AIs), and overall AET (tamoxifen or AIs) within the first 12 months of diagnosis.
Epidemiological and Mendelian randomisation studies of dihydrotestosterone and estradiol, and leucocyte telomere length in men.
New
Beilby et al., Australia. In J Clin Endocrinol Metab, Feb 2016
Testosterone (T) is metabolised to dihydrotestosterone (DHT) by 5|ga-reductase (SRD5A2) and to estradiol (E2) by aromatase (CYP19A1).
Exercise adherence in a randomized trial of exercise on aromatase inhibitor arthralgias in breast cancer survivors: the Hormones and Physical Exercise (HOPE) study.
New
Irwin et al., Bethesda, United States. In J Cancer Surviv, Feb 2016
PURPOSE: Up to 50 % of postmenopausal breast cancer survivors taking aromatase inhibitors (AIs) experience AI-associated arthralgias, or joint pain, which causes many to stop taking AIs and may inhibit exercise, despite known health benefits.
Impact of Adjuvant Endocrine Therapy on Quality of Life and Symptoms: Observational Data Over 12 Months From the Mind-Body Study.
New
Impact
Crespi et al., Los Angeles, United States. In J Clin Oncol, Feb 2016
Longitudinal trajectories of outcome variables among three patient groups (no ET, aromatase inhibitor [AI], or tamoxifen) were compared by using linear mixed models.
Structural basis for olivetolic acid formation by a polyketide cyclase from Cannabis sativa.
New
Morita et al., Toyama, Japan. In Febs J, Feb 2016
Structural and/or functional studies of OAC suggested that the enzyme lacks thioesterase and aromatase activities.
Resveratrol for breast cancer prevention and therapy: Preclinical evidence and molecular mechanisms.
Review
New
Bishayee et al., Calcutta, India. In Semin Cancer Biol, Feb 2016
The roles of resveratrol as a phytoestrogen, an aromatase inhibitor and in stem cell therapy as well as adjuvent treatment are also discussed.
Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention Trial.
New
Impact
Cuzick et al., Manchester, United Kingdom. In J Clin Oncol, Feb 2016
It has been suggested that hormonal risk factors may be involved in the pathogenesis of CTS, and a higher incidence of CTS has been reported in randomized clinical trials with aromatase inhibitors (AIs) compared with tamoxifen.
Ultra-high sensitivity analysis of estrogens for special populations in serum and plasma by liquid chromatography-mass spectrometry: assay considerations and suggested practices.
Review
New
Blair et al., Philadelphia, United States. In J Steroid Biochem Mol Biol, Feb 2016
It remains an analytical challenge to quantify estrogens and their metabolites in specimens from special populations including older men, children, postmenopausal women and women receiving aromatase inhibitors.
Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.
New
Impact
Regan et al., Valencia, Spain. In J Clin Oncol, Feb 2016
CONCLUSION: During the first year, most patients on exemestane plus triptorelin had E2 levels below the defined threshold of 2.72 pg/mL, consistent with levels reported in postmenopausal patients on aromatase inhibitors, but at each time point, at least 17% of patients had levels greater than the threshold.
Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial.
New
Impact
IBIS-II investigators et al., Newcastle, Australia. In Lancet, Jan 2016
BACKGROUND: Third-generation aromatase inhibitors are more effective than tamoxifen for preventing recurrence in postmenopausal women with hormone-receptor-positive invasive breast cancer.
Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial.
New
Impact
Wolmark et al., Pittsburgh, United States. In Lancet, Jan 2016
We postulated that an aromatase inhibitor would be safer and more effective.
High-Dose Hook Effect in 17-Hydroxyprogesterone Assay in a Patient with 21-Hydroxylase Deficiency.
New
Türkkahraman et al., Antalya, Turkey. In J Clin Res Pediatr Endocrinol, Jan 2016
Additionally, this case demonstrates that a high testosterone level can block aromatase activity and consequently also estrogen production and breast development.
Neoadjuvant endocrine treatment in early breast cancer: An overlooked alternative?
Review
New
Trinh et al., Antwerp, Belgium. In Eur J Surg Oncol, Dec 2015
In studies comparing tamoxifen with aromatase inhibitors (AI), AI proved to be superior in terms of tumour response and rates of BCS.
Compounded Testosterone Troches TO OPTIMIZE HEALTH AND THE TESTOSTERONE CONTROVERSY.
Review
New
Guth, In Int J Pharm Compd, May 2015
The current state-of-the-art in testosterone replacement therapy comprises compounded testosterone troches; an aromatase inhibitor, such as generic Anastrazole, to control estradiol levels; and a 5α-reductase inhibitor, such as beneric Dutasteride or Finasteride, to control dihydrotestosterone.
Treatment of Intravenous Leiomyomatosis with Cardiac Extension following Incomplete Resection.
Review
Robertson et al., Sydney, Australia. In Int J Vasc Med, 2014
The uses of progesterone, estrogen modulation, gonadotropin-releasing hormone antagonism, and aromatase inhibition have been described following incomplete resection.
Aromatase, steroid-5-alpha-reductase type 1 and type 2 mRNA expression in gonads and in brain of Xenopus laevis during ontogeny.
GeneRIF
Kloas et al., Berlin, Germany. In Gen Comp Endocrinol, 2007
The ontogenetic patterns of Aro, Srd5a1 and Srd5a2 suggest that these genes are involved in sexual differentiation of gonads and brain already in early developmental stages.
Expression of the gonadal p450 aromatase gene of Xenopus and characterization of the 5'-flanking region of the aromatase gene.
GeneRIF
Miyata et al., Tokyo, Japan. In J Steroid Biochem Mol Biol, 2005
binding sequences to a specific trans-activating factor upstream of the p450 aromatase promoter II
share on facebooktweetadd +1mail to friends